U.S. Markets close in 5 hrs 5 mins

AbbVie Has Issues, But It Isn't the 'Next Big Drug Short'

Max Nisen
AbbVie Has Issues, But It Isn't the 'Next Big Drug Short'

Citron tweeted Thursday that AbbVie was “the next great drug short” and that its 12-month price target was $60. The drug is protected by a robust wall of patents that several companies have  failed to batter down.